ConductScience.org, home

Paper2437455

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Williams SD and 5 others. N Engl J Med, 1987. Cited by 1,031 papers, by iCite.

Cite this record

ConductScience Library. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. Papers, record 2437455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2437455

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
PubMed
Journal
N Engl J Med
PubMed
Year
1987
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
1,031
iCite
Relative citation ratio, by iCite
32.6
iCite
Revised in PubMed
2013-11-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Williams SDS D
2Birch RR
3Einhorn LHL H
4Irwin LL
5Greco FAF A
6Loehrer PJP J

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Neoplasms, Germ Cell and EmbryonalMajor topic
Bleomycin
Cisplatin
Clinical Trials as Topic
Drug Administration Schedule
Etoposide
Female
Humans
Male
Random Allocation
Vinblastine

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
2 R35 CA 39844-02NCI NIH HHSUnited StatesR35CA398440PubMedNIH RePORTER
CA 24456NCI NIH HHSUnited StatesR10CA024456PubMed and NIHNIH RePORTER
MO 1-RR00-750-15NCRR NIH HHSUnited StatesMO1RR007501PubMedNIH RePORTER
M01RR000750NIHNIH RePORTER
R35CA039844NIHNIH RePORTER
U10CA024456NIHNIH RePORTER

Download CSV of grants

Cited by208

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,031 citations.

PMIDTitleJournalYearIn PapersSource
42271363Clinical outcomes of a 3-day modified BEP regimen in malignant ovarian germ cell tumors in a single-center real-world study.World J Surg Oncol2026https://conductscience.org/library/papers/42271363PubMed
41001186Updates in the Management of Malignant Ovarian Germ Cell Tumors.O G Open2025https://conductscience.org/library/papers/41001186PubMed
40947516Outcome of Children With Intermediate-Risk Extracranial Malignant Germ Cell Tumors by Response Status at the End of Induction Chemotherapy: A Report From the Children's Oncology Group.Pediatr Blood Cancer2025https://conductscience.org/library/papers/40947516PubMed
40572639Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey.Medicina (Kaunas)2025https://conductscience.org/library/papers/40572639PubMed
40515472Adverse health outcomes in testis cancer survivors-the price for our success?Oncologist2025https://conductscience.org/library/papers/40515472PubMed
40098231
Standard-Dose Versus High-Dose Cisplatin for Intermediate/Poor-Risk Extracranial Malignant Germ Cell Tumors: Re-Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification.
Pediatr Blood Cancer2025https://conductscience.org/library/papers/40098231PubMed
39432183The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing.Pharmacol Rep2025https://conductscience.org/library/papers/39432183PubMed
39386925Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors?Gynecol Oncol Rep2024https://conductscience.org/library/papers/39386925PubMed
39046545Detection of vinblastine and related bioactive compounds from culture extracts of endophytic fungi of Catharanthus roseus.World J Microbiol Biotechnol2024https://conductscience.org/library/papers/39046545PubMed
38929965Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer.J Clin Med2024https://conductscience.org/library/papers/38929965PubMed
38074010Testicular Germ Cell Tumors in Children and Adolescents Treated With Bleomycin, Etoposide, and Cisplatin (BEP) Protocol: A Survival Analysis.Cureus2023https://conductscience.org/library/papers/38074010PubMed
37564420Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States.Lancet Reg Health Am2023https://conductscience.org/library/papers/37564420PubMed
37149691Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence.Nat Commun2023https://conductscience.org/library/papers/37149691PubMed
37046659Pediatric Extracranial Germ Cell Tumors: Review of Clinics and Perspectives in Application of Autologous Stem Cell Transplantation.Cancers (Basel)2023https://conductscience.org/library/papers/37046659PubMed
36947730The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol2023https://conductscience.org/library/papers/36947730PubMed
36882564Treatment de-escalation for stage II seminoma.Nat Rev Urol2023https://conductscience.org/library/papers/36882564PubMed
36477219High-dose chemotherapy for relapsed testicular germ cell tumours.Nat Rev Urol2023https://conductscience.org/library/papers/36477219PubMed
36340558Bleomycin-Induced Fulminant Hyperpyrexia: A Report of Two Cases and Review of Literature.Cureus2022https://conductscience.org/library/papers/36340558PubMed
35111449From Cancer Patient to Provider: An Autobiographical Case Report.Cureus2021https://conductscience.org/library/papers/35111449PubMed
34738090
Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial.
Eur Urol Open Sci2021https://conductscience.org/library/papers/34738090PubMed

See all 208 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2437455

GET https://conductscience.org/api/papers/v1/2437455/cited_by?page=2